Key result
Outpatient furosemide infusion linked to ~6-9% 30-day readmission rates and substantial annual cost savings.
Why the study?
Heart failure causes significant morbidity, mortality, and financial burden, motivating an evaluation of 30-day readmissions and hospital financial impact associated with an outpatient diuretic infusion program.
Does outpatient furosemide infusion reduce 30-day hospital readmissions and healthcare costs in adult heart failure patients recently readmitted despite guideline-directed medical therapy?
Observational (n=56)
No
Does outpatient furosemide infusion reduce 30-day hospital readmissions and healthcare costs in adult heart failure patients recently readmitted despite guideline-directed medical therapy?
An outpatient diuretic infusion clinic administering IV furosemide to heart failure patients is associated with low 30-day readmission rates and significant hospital cost savings.
Answers are grounded in this paper and cite their sources.
May support outpatient furosemide infusion in select HF patients; leaves open randomized confirmation before practice change.
Background and Objectives: Heart failure (HF) is a complex syndrome with multiple etiologies resulting in impaired ventricular filling or pumping of blood. HF is as a major public health concern that leads to significant morbidity and mortality resulting in an enormous financial burden on the healthcare system. The study objectives were to assess the 30-day hospital readmission rates and its financial impact on the hospital. Methods: The study was a retrospective single-center analysis of decoded data of all HF patients admitted to an outpatient diuretic infusion program. Adult patients who were readmitted to the hospital within 30 days despite guideline derive medical therapy were included if they were enrolled in the outpatient diuretic infusion clinic. Adult patients who were included in this study received a furosemide dose of 40 mg intravenously (infusion over 3 hours) at the clinic visit. Patients whose clinical signs/symptoms improved and remained stable in consequent visits were eventually discharged from the clinic. Financial impact was assessed using data obtained from the hospital administration on cost of HF readmissions. Results: The results show a 30-day hospital readmission rate at 6-9% in the years analyzed (n=56) with a net savings of $562,815 to $736,560 per year. Conclusions: This treatment strategy has no detrimental effects in addition to generating substantial financial savings. It appears to be a useful addition to the existing medical treatment regimens chronic HF patients.
No takes yet. Share an insight, caveat, or question.
Nair et al. (2022) conducted an observational in Heart failure (n=56). Outpatient furosemide infusion therapy was evaluated on 30-day hospital readmission rate. Outpatient furosemide infusion therapy resulted in a 30-day hospital readmission rate of 6-9% and generated a net savings of $562,815 to $736,560 per year.
Synapse has enriched 10 related papers. Consider them for comparative context: